Equities analysts predict that OptimizeRx Co. (NASDAQ:OPRX) will announce earnings of $0.14 per share for the current quarter, Zacks Investment Research reports. Two analysts have issued estimates for OptimizeRx’s earnings, with the lowest EPS estimate coming in at $0.13 and the highest estimate coming in at $0.14. OptimizeRx posted earnings of $0.07 per share in the same quarter last year, which would indicate a positive year-over-year growth rate of 100%. The firm is expected to issue its next quarterly earnings report on Monday, November 8th.
According to Zacks, analysts expect that OptimizeRx will report full year earnings of $0.51 per share for the current fiscal year, with EPS estimates ranging from $0.49 to $0.52. For the next year, analysts anticipate that the business will post earnings of $0.76 per share, with EPS estimates ranging from $0.74 to $0.78. Zacks’ EPS averages are a mean average based on a survey of analysts that that provide coverage for OptimizeRx.
OptimizeRx (NASDAQ:OPRX) last issued its quarterly earnings results on Wednesday, August 4th. The company reported $0.10 EPS for the quarter, topping analysts’ consensus estimates of $0.02 by $0.08. The business had revenue of $13.63 million during the quarter, compared to the consensus estimate of $12.35 million. OptimizeRx had a net margin of 3.98% and a return on equity of 2.26%.
In related news, CFO Douglas P. Baker sold 4,000 shares of the firm’s stock in a transaction dated Thursday, June 24th. The stock was sold at an average price of $60.00, for a total value of $240,000.00. Following the transaction, the chief financial officer now owns 86,217 shares in the company, valued at $5,173,020. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Stephen L. Silvestro sold 13,242 shares of the firm’s stock in a transaction dated Thursday, June 17th. The shares were sold at an average price of $53.44, for a total value of $707,652.48. Following the completion of the transaction, the insider now owns 13,242 shares in the company, valued at approximately $707,652.48. The disclosure for this sale can be found here. Insiders have sold 89,582 shares of company stock valued at $5,143,945 over the last quarter. Corporate insiders own 6.50% of the company’s stock.
Institutional investors and hedge funds have recently modified their holdings of the business. Eaton Vance Management bought a new position in OptimizeRx during the first quarter worth about $31,000. Jacobi Capital Management LLC bought a new position in OptimizeRx during the first quarter worth about $34,000. Altshuler Shaham Ltd bought a new position in OptimizeRx during the first quarter worth about $41,000. FORA Capital LLC bought a new position in OptimizeRx during the first quarter worth about $48,000. Finally, HighMark Wealth Management LLC lifted its holdings in shares of OptimizeRx by 2,188.6% during the 2nd quarter. HighMark Wealth Management LLC now owns 1,007 shares of the company’s stock valued at $62,000 after purchasing an additional 963 shares in the last quarter. Hedge funds and other institutional investors own 67.39% of the company’s stock.
OPRX opened at $65.12 on Friday. The company’s 50 day simple moving average is $60.27 and its 200 day simple moving average is $54.08. OptimizeRx has a 1 year low of $17.01 and a 1 year high of $73.88. The stock has a market capitalization of $1.15 billion, a PE ratio of 542.67 and a beta of 0.66.
OptimizeRx Corp. is digital health company, which engages in the provision of digital health messaging via electronic health records, which serves as a direct channel for pharmaceutical companies to communicate with healthcare providers. It offers electronic health record (EHR) workflow solutions which include financial messaging, patient education, and brand messaging; and brand support.
Featured Story: What strategies should day traders use to execute a trade?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for OptimizeRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OptimizeRx and related companies with MarketBeat.com's FREE daily email newsletter.